- Home
- ACXP vs RAPT Comparison
ACXP vs RAPT Comparison
Compare ACXP & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- RAPT
- Stock Information
- Founded
- ACXP 2017
- RAPT 2015
- Country
- ACXP United States
- RAPT United States
- Employees
- ACXP N/A
- RAPT N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- RAPT Health Care
- Exchange
- ACXP Nasdaq
- RAPT Nasdaq
- Market Cap
- ACXP 31.4M
- RAPT 30.8M
- IPO Year
- ACXP 2021
- RAPT 2019
- Fundamental
- Price
- ACXP $0.87
- RAPT $0.89
- Analyst Decision
- ACXP Strong Buy
- RAPT Hold
- Analyst Count
- ACXP 1
- RAPT 10
- Target Price
- ACXP $12.00
- RAPT $5.00
- AVG Volume (30 Days)
- ACXP 297.3K
- RAPT 394.7K
- Earning Date
- ACXP 11-12-2024
- RAPT 11-12-2024
- Dividend Yield
- ACXP N/A
- RAPT N/A
- EPS Growth
- ACXP N/A
- RAPT N/A
- EPS
- ACXP N/A
- RAPT N/A
- Revenue
- ACXP N/A
- RAPT N/A
- Revenue This Year
- ACXP N/A
- RAPT N/A
- Revenue Next Year
- ACXP N/A
- RAPT N/A
- P/E Ratio
- ACXP N/A
- RAPT N/A
- Revenue Growth
- ACXP N/A
- RAPT N/A
- 52 Week Low
- ACXP $0.72
- RAPT $0.84
- 52 Week High
- ACXP $5.28
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- ACXP 31.17
- RAPT 36.23
- Support Level
- ACXP $0.84
- RAPT $0.84
- Resistance Level
- ACXP $0.91
- RAPT $1.18
- Average True Range (ATR)
- ACXP 0.12
- RAPT 0.10
- MACD
- ACXP 0.02
- RAPT 0.01
- Stochastic Oscillator
- ACXP 28.07
- RAPT 17.00
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.